About Kallyope
Kallyope uses the science of gut-brain biology to create medicines that transform human health.
Headquarters
Kallyope, New York
Founded
2015-01-01
Industry
Biotechnology, Health Care, Medical, Pharmaceutical
Last Funding Type
Grant
Valuation
1
Total Funding
$487.20 million dollars
IPO Status
Private
Financial
Kallyope is focused on developing therapies targeting the gut-brain axis. Their research includes GPR119 and GPR40 agonist combination therapies for metabolic disorders and gut-brain axis conditions. They are also investigating NK3 modulators for various headache disorders. Additionally, Kallyope is working on AMPK activators for conditions associated with AMPK and the gut-brain axis, as well as systems for associating genes with phenotypes. Their R&D efforts are concentrated on creating treatments that are gut-restricted and potentially beneficial for metabolic and systemic disorders.
Kallyope Inc., a biotech firm focusing on oral weight loss drugs, is reportedly considering an initial public offering (IPO). This move comes as the company seeks to capitalize on its developments in obesity treatments, highlighting a significant step in its business strategy.
Kallyope Inc., a biotech firm focusing on oral weight loss drugs, is reportedly considering an initial public offering (IPO). This move comes as the company seeks to capitalize on its developments in obesity treatments, highlighting a significant step in its business strategy.
Funding Rounds
6
Number of Lead Investors
5
Total Funding Amount
$487.20 million dollars
Number of Investors
19